Aethlon Medical Inc (AEMD) 0.2075 $AEMD
Market Maker Surveillance Report. AEMD, SIRI, JPM, DDR, RF, FB, Highest Net Buy Volume With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Aethlon Medical Inc (OTC:AEMD), Sirius XM Radio Inc (NASDAQ:SIRI), JPMorgan Chase & Co (NYSE:JPM), DDR Corp (NYSE
DR), Regions Financial Corp (NYSE:RF), Facebook Inc (NASDAQ:FB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
DDR: 17.55 (+0.22), RF: 9.26 (unch), JPM: 57.45 (-0.48), FB: 78.37 (-0.32), SIRI: 3.33 (-0.05)
Aethlon Medical Announces First Treatment of an Ebola Patient
PR Newswire - Tue Oct 14, 6:15AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
Market Maker Surveillance Report. AEMD, KO, PFE, PG, CVS, GXP, Bullishly Biased Price Friction For Friday, October 10th 2014
M2 - Mon Oct 13, 4:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4739 companies with "abnormal" market making, 1125 companies with positive Friction Factors and 3963 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Aethlon Medical Inc (OTC:AEMD), The Coca-Cola Co (NYSE:KO), Pfizer Inc (NYSE
FE), Procter & Gamble Co (NYSE G), CVS Caremark Corp (NYSE:CVS), Great Plains Energy Inc (NYSE:GXP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KO: 40.62 (-0.06), GXP: 26.15 (+0.22), PFE: 28.30 (+0.02), CVS: 83.25 (+0.33), PG: 84.23 (-0.38)
SeeThruEquity Issues Company Note on Aethlon Medical and Increase Target Price to $0.52
ACCESSWIRE - Tue Oct 07, 8:05AM CDT
Company Announces Collaboration with Boston University CTE Center and Expanded Hemopurifier Clinical Studies
Aethlon Medical, Inc. - "A Pivotal Moment That Changed the NFL and CTE Research"
ACCESSWIRE - Tue Oct 07, 7:41AM CDT
New York, NY / October 7, 2014 / Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players
PR Newswire - Fri Sep 26, 7:31AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.
Aethlon Medical Announces Dengue Virus Treatment Agreement
PR Newswire - Wed Sep 24, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into an agreement with Qualtran, LLC that would expand human clinical studies of Hemopurifier® therapy to include individuals infected with dengue virus, a global health threat, which is not addressed with approved drug or vaccine therapies. Aethlon is also in the process of initiating the first FDA approved study of Hemopurifier® therapy in individuals infected with hepatitis c virus (HCV).
Aethlon Medical Receives Notice of DARPA Contract Renewal
PR Newswire - Mon Sep 22, 9:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that the Defense Advanced Research Projects Agency (DARPA) has informed the Company that it plans to exercise an option to proceed with year four of a five-year $5.9 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.
SeeThruEquity Initiates Research Coverage on Aethlon Medical, Inc. with Target Price of $0.34
ACCESSWIRE - Mon Sep 22, 8:03AM CDT
New York, NY / ACCESSWIRE / September 22, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Aethlon Medical, Inc. (OTCQB: AEMD), a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit
PR Newswire - Wed Sep 17, 1:49PM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that each company will be presenting at the 2014 Exosomes & SingleCell Analysis Summit.
Aethlon Medical Inc. - "The Identification of Neurological Disorders in NFL Players"
ACCESSWIRE - Tue Sep 16, 8:32AM CDT
New York, NY / September 16, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical Inc. - "The Ebola, Dengue, Enterovirus, and Chikungunya Outbreaks"
ACCESSWIRE - Wed Sep 10, 8:15AM CDT
New York, NY / September 10, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. Launches Digital Corporate Communication Channels
PR Newswire - Wed Sep 10, 8:01AM CDT
Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.
Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
PR Newswire - Mon Sep 08, 7:31AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.
Aethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies
PR Newswire - Tue Sep 02, 8:30AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas.
Aethlon Medical (AEMD) CEO Note: A Novel Strategy To Address Ebola
PR Newswire - Wed Aug 06, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
INCY: 52.47 (+0.03), MRK: 55.51 (+0.38), BMY: 51.84 (-0.11), GSK: 44.41 (+0.78), NVS: 88.20 (-0.41), CELG: 94.76 (-0.21), CELGZ: 3.54 (-0.03)
Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation
PR Newswire - Wed Jun 25, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.
Aethlon Medical to Present at The Wall Street Analyst Forum
PR Newswire - Tue Jun 17, 11:53AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier®, a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.
Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Market Maker Surveillance Report. AEMD, SIRI, JPM, DDR, RF, FB, Highest Net Buy Volume With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Aethlon Medical Inc (OTC:AEMD), Sirius XM Radio Inc (NASDAQ:SIRI), JPMorgan Chase & Co (NYSE:JPM), DDR Corp (NYSE
DR), Regions Financial Corp (NYSE:RF), Facebook Inc (NASDAQ:FB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . DDR: 17.55 (+0.22), RF: 9.26 (unch), JPM: 57.45 (-0.48), FB: 78.37 (-0.32), SIRI: 3.33 (-0.05)
Aethlon Medical Announces First Treatment of an Ebola Patient
PR Newswire - Tue Oct 14, 6:15AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
Market Maker Surveillance Report. AEMD, KO, PFE, PG, CVS, GXP, Bullishly Biased Price Friction For Friday, October 10th 2014
M2 - Mon Oct 13, 4:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4739 companies with "abnormal" market making, 1125 companies with positive Friction Factors and 3963 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Aethlon Medical Inc (OTC:AEMD), The Coca-Cola Co (NYSE:KO), Pfizer Inc (NYSE
FE), Procter & Gamble Co (NYSE G), CVS Caremark Corp (NYSE:CVS), Great Plains Energy Inc (NYSE:GXP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . KO: 40.62 (-0.06), GXP: 26.15 (+0.22), PFE: 28.30 (+0.02), CVS: 83.25 (+0.33), PG: 84.23 (-0.38)
SeeThruEquity Issues Company Note on Aethlon Medical and Increase Target Price to $0.52
ACCESSWIRE - Tue Oct 07, 8:05AM CDT
Company Announces Collaboration with Boston University CTE Center and Expanded Hemopurifier Clinical Studies
Aethlon Medical, Inc. - "A Pivotal Moment That Changed the NFL and CTE Research"
ACCESSWIRE - Tue Oct 07, 7:41AM CDT
New York, NY / October 7, 2014 / Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players
PR Newswire - Fri Sep 26, 7:31AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.
Aethlon Medical Announces Dengue Virus Treatment Agreement
PR Newswire - Wed Sep 24, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into an agreement with Qualtran, LLC that would expand human clinical studies of Hemopurifier® therapy to include individuals infected with dengue virus, a global health threat, which is not addressed with approved drug or vaccine therapies. Aethlon is also in the process of initiating the first FDA approved study of Hemopurifier® therapy in individuals infected with hepatitis c virus (HCV).
Aethlon Medical Receives Notice of DARPA Contract Renewal
PR Newswire - Mon Sep 22, 9:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that the Defense Advanced Research Projects Agency (DARPA) has informed the Company that it plans to exercise an option to proceed with year four of a five-year $5.9 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.
SeeThruEquity Initiates Research Coverage on Aethlon Medical, Inc. with Target Price of $0.34
ACCESSWIRE - Mon Sep 22, 8:03AM CDT
New York, NY / ACCESSWIRE / September 22, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Aethlon Medical, Inc. (OTCQB: AEMD), a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit
PR Newswire - Wed Sep 17, 1:49PM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that each company will be presenting at the 2014 Exosomes & SingleCell Analysis Summit.
Aethlon Medical Inc. - "The Identification of Neurological Disorders in NFL Players"
ACCESSWIRE - Tue Sep 16, 8:32AM CDT
New York, NY / September 16, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical Inc. - "The Ebola, Dengue, Enterovirus, and Chikungunya Outbreaks"
ACCESSWIRE - Wed Sep 10, 8:15AM CDT
New York, NY / September 10, 2014 / Aethlon Medical Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. Launches Digital Corporate Communication Channels
PR Newswire - Wed Sep 10, 8:01AM CDT
Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.
Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
PR Newswire - Mon Sep 08, 7:31AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.
Aethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies
PR Newswire - Tue Sep 02, 8:30AM CDT
Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas.
Aethlon Medical (AEMD) CEO Note: A Novel Strategy To Address Ebola
PR Newswire - Wed Aug 06, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
INCY: 52.47 (+0.03), MRK: 55.51 (+0.38), BMY: 51.84 (-0.11), GSK: 44.41 (+0.78), NVS: 88.20 (-0.41), CELG: 94.76 (-0.21), CELGZ: 3.54 (-0.03)
Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation
PR Newswire - Wed Jun 25, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.
Aethlon Medical to Present at The Wall Street Analyst Forum
PR Newswire - Tue Jun 17, 11:53AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier®, a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.
Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
